FH Deficient

CI-VAR-00000626Explore in graph →CIViC 5455

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Hereditary Renal Cell Carcinoma1
FH Deficient	Bevacizumab + ErlotinibCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID12939 In the open‑label phase II AVATAR trial (NCT01130519), patients with HLRCC‑associated papillary RCC harboring germline FH pathogenic variants (n = 43) received erlotinib plus bevacizumab, with ORR as … (full text at CIViC) PMID 40532152 · Srinivasan et al., 2025 · Open in CIViC	civic
Papillary Renal Cell Carcinoma1
FH Deficient	Bevacizumab + ErlotinibCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID12940

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.